These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 32780215)

  • 21. Strategies to Optimize Dual Antiplatelet Therapy After Coronary Artery Stenting in Acute Coronary Syndrome.
    Paravattil B; Elewa H
    J Cardiovasc Pharmacol Ther; 2017 Jul; 22(4):347-355. PubMed ID: 28587584
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Short-term dual antiplatelet therapy (DAPT) followed by P2Y12 monotherapy versus traditional DAPT in patients undergoing percutaneous coronary intervention: meta-analysis and viewpoint.
    Wernly B; Rezar R; Gurbel P; Jung C
    J Thromb Thrombolysis; 2020 Jan; 49(1):173-176. PubMed ID: 31686298
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Aspirin-free antiplatelet strategies after percutaneous coronary interventions.
    Capranzano P; Moliterno D; Capodanno D
    Eur Heart J; 2024 Feb; 45(8):572-585. PubMed ID: 38240716
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Shorter (≤6 months) versus longer (≥12 months) duration dual antiplatelet therapy after drug eluting stents: a meta-analysis of randomized clinical trials.
    Pandit A; Giri S; Hakim FA; Fortuin FD
    Catheter Cardiovasc Interv; 2015 Jan; 85(1):34-40. PubMed ID: 24753084
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and Safety of P2Y
    Casula M; Casu G; Talanas G; Spano A; Tantry U; Bilotta F; Micheluzzi V; Merella P; Porcheddu T; Gorog DA; Bonaca M; Jeong YH; Farkouh ME; Kubica J; Isgender M; Gurbel PA; Navarese EP
    Curr Probl Cardiol; 2024 Aug; 49(8):102635. PubMed ID: 38750991
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of aspirin treatment duration on clinical outcomes in acute coronary syndrome patients with early aspirin discontinuation and received P2Y12 inhibitor monotherapy.
    Ho MY; Chen PW; Feng WH; Su CH; Huang SW; Cheng CW; Yeh HI; Chen CP; Huang WC; Fang CC; Lin HW; Lin SH; Hsieh IC; Li YH
    PLoS One; 2021; 16(5):e0251109. PubMed ID: 33979377
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Optimal duration of dual antiplatelet therapy post percutaneous coronary intervention in acute coronary syndrome.
    Deharo P; Cuisset T
    Trends Cardiovasc Med; 2020 May; 30(4):198-202. PubMed ID: 31182263
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Guanxinning tablet for patients who switch from dual antiplatelet therapy to aspirin alone after percutaneous coronary intervention: study protocol for a cluster randomized controlled trial.
    Li J; Ju J; Chen Z; Liu J; Lu F; Gao R; Xu H
    Trials; 2018 Feb; 19(1):93. PubMed ID: 29415754
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antiplatelet Therapy in Patients Undergoing Elective Percutaneous Coronary Intervention.
    Alkhalil M; Džavík V; Bhatt DL; Mehran R; Mehta SR
    Curr Cardiol Rep; 2022 Mar; 24(3):277-293. PubMed ID: 35294730
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI: The STOPDAPT-2 Randomized Clinical Trial.
    Watanabe H; Domei T; Morimoto T; Natsuaki M; Shiomi H; Toyota T; Ohya M; Suwa S; Takagi K; Nanasato M; Hata Y; Yagi M; Suematsu N; Yokomatsu T; Takamisawa I; Doi M; Noda T; Okayama H; Seino Y; Tada T; Sakamoto H; Hibi K; Abe M; Kawai K; Nakao K; Ando K; Tanabe K; Ikari Y; Hanaoka KI; Morino Y; Kozuma K; Kadota K; Furukawa Y; Nakagawa Y; Kimura T;
    JAMA; 2019 Jun; 321(24):2414-2427. PubMed ID: 31237644
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Duration of dual antiplatelet therapy after percutaneous coronary intervention with implantation of second-generation drug-eluting stent: A meta-analysis of randomized controlled trials.
    Liu D; Li YZ; Wu H; Yang J; Yang J; Ding J-; Zhang J; Fan Z-; Yang CJ
    Pharmazie; 2020 Apr; 75(4):113-117. PubMed ID: 32295685
    [No Abstract]   [Full Text] [Related]  

  • 32. Current developments in dual antiplatelet therapy after stenting.
    Giacoppo D; Baber U; Mehran R
    Minerva Cardioangiol; 2014 Jun; 62(3):261-76. PubMed ID: 24831762
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and efficacy of antiplatelet regimens after percutaneous coronary intervention using drug eluting stents: A network meta-analysis of randomized controlled trials.
    Garg A; Rout A; Sharma A; Sargsyan D; Beavers T; Tantry U; Gurbel P; Rao SV; Kostis JB; Cohen M
    Prog Cardiovasc Dis; 2020; 63(3):243-248. PubMed ID: 32247786
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Short dual antiplatelet therapy followed by P2Y12 inhibitor monotherapy vs. prolonged dual antiplatelet therapy after percutaneous coronary intervention with second-generation drug-eluting stents: a systematic review and meta-analysis of randomized clinical trials.
    Giacoppo D; Matsuda Y; Fovino LN; D'Amico G; Gargiulo G; Byrne RA; Capodanno D; Valgimigli M; Mehran R; Tarantini G
    Eur Heart J; 2021 Jan; 42(4):308-319. PubMed ID: 33284979
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety of 3-Month Dual Antiplatelet Therapy After Implantation of Ultrathin Sirolimus-Eluting Stents With Biodegradable Polymer (Orsiro): Results From the SMART-CHOICE Trial.
    Yun KH; Lee SY; Cho BR; Jang WJ; Song YB; Oh JH; Chun WJ; Park YH; Im ES; Jeong JO; Oh SK; Cho DK; Lee JY; Koh YY; Bae JW; Choi JW; Lee WS; Yoon HJ; Lee SU; Cho JH; Choi WG; Rha SW; Lee JM; Park TK; Yang JH; Choi JH; Choi SH; Lee SH; Gwon HC; Hahn JY;
    J Am Heart Assoc; 2021 Jan; 10(1):e018366. PubMed ID: 33345567
    [TBL] [Abstract][Full Text] [Related]  

  • 36. P2Y12 Inhibitor Monotherapy Versus Conventional Dual Antiplatelet Therapy or Aspirin Monotherapy in Acute Coronary Syndrome: A Pooled Analysis of the SMART-DATE and SMART-CHOICE Trials.
    Song PS; Park YH; Oh JH; Song YB; Choi SH; Gwon HC; Cho DK; Rha SW; Bae JW; Jeong JO; Hahn JY;
    Am J Cardiol; 2021 Jul; 150():47-54. PubMed ID: 34011436
    [TBL] [Abstract][Full Text] [Related]  

  • 37. P2Y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularisation: individual patient level meta-analysis of randomised controlled trials.
    Valgimigli M; Gragnano F; Branca M; Franzone A; Baber U; Jang Y; Kimura T; Hahn JY; Zhao Q; Windecker S; Gibson CM; Kim BK; Watanabe H; Song YB; Zhu Y; Vranckx P; Mehta S; Hong SJ; Ando K; Gwon HC; Serruys PW; Dangas GD; McFadden EP; Angiolillo DJ; Heg D; Jüni P; Mehran R
    BMJ; 2021 Jun; 373():n1332. PubMed ID: 34135011
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term antiplatelet therapy following myocardial infarction: implications of PEGASUS-TIMI 54.
    Parker WA; Storey RF
    Heart; 2016 May; 102(10):783-9. PubMed ID: 26857211
    [TBL] [Abstract][Full Text] [Related]  

  • 39. P2Y12 Inhibitors Plus Aspirin Versus Aspirin Alone in Patients With Minor Stroke or High-Risk Transient Ischemic Attack.
    Li ZX; Xiong Y; Gu HQ; Fisher M; Xian Y; Johnston SC; Wang YJ
    Stroke; 2021 Jul; 52(7):2250-2257. PubMed ID: 34039032
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Optimal duration of dual antiplatelet therapy after PCI: integrating procedural complexity, bleeding risk and the acuteness of clinical presentation.
    Chen H; Power D; Giustino G
    Expert Rev Cardiovasc Ther; 2018 Oct; 16(10):735-748. PubMed ID: 30221557
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.